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ABSTRACT 
 
A  Novel  floating  controlled  release  drug  delivery  system  of  famotidine  was  formulated  in an  effort  to  
increase  the  gastric  retention  time  of  the  dosage  form  and  to  control  drug  release. The  present  work  
investigates  the  approach  using  two  different  polymers  HPMC K100 M  and  natural  polymer  Chitosan . A  
floating  drug  delivery  system  (FDDS)  was developed  using  gas-forming  agents,  like  sodium  bicarbonate,  
citric  acid  and hydrocolloids,  like  hydroxyl  propyl  methylcellulose (HPMC),  MCC,  PvP k30   and   chitosan.  
The  prepared  tablets  were  evaluated  in  terms  of  their  precompression  parameters,  physical  characteristics,  in 
vitro  release,  buoyancy  and  buoyancy  lag-time. Famotidine effervescent floating tablets  were  developed  by  
direct  compression  technique. F5  formulation  showed  maximum   floating   time   of   17  hours   and   gave   
controlled  and   maximum   drug   release  of  over  17h.Therefore   the   formulation   F5   found  to  be optimized,  
to achieve  the  goal  of  formulation   and  evaluation  of  effervescent  floating   tablet   of   famotidine.  The   effect   
of  citric   acid  on a  floating  properties  and  drug  release  profile  was  also  investigated. A combination  of  
sodium  bicarbonate  and  citric  acid  was  found  to  achieve  required  in-vitro buoyancy.  
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Introduction 
 
 
Floating  tablets  are  used  to  increase  the  gastric  
residence  time  of  active  pharmaceutical ingredients. 
To  overcome  the  limitations  of  conventional  drug  
delivery  system  the  floating tablets  were  developed. 
Drugs  that  have  narrow  absorption  window  in  the  
gastrointestinal tract (GIT) will  have  poor  absorption. 
For  these  drugs,  gastro  retentive  drug  delivery 
systems  offer  the  advantages  in  prolonging  the  
gastric  emptying  time.  
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The  uniform distribution  of  these  multiple  unit  
dosage  forms  along  the  GIT, could  result  in  more 
reproducible  drug  absorption  and  reduced  risk  of  
local  irritation; this  gave  birth  to oral controlled  
drug  delivery  and  led  to  development  of  Gastro-
retentive  floating  systems. Floating  drug  delivery  
systems  were  first  described  by  Davis  in  1968[1]. 
Famotidine  is  histamine [H2-receptor] antagonist  and  
is  widely  prescribed  in  gastric  ulcers, duodenal  
ulcers, Zollinger Ellision  syndrome  and  gastro  
esophageal  reflux  disease. They also  find  use  in  the  
management  of  benign  gastric  and  duodenal  
ulceration.  The  standard therapeutic  dose  is  40  mg  
daily,  orally  at  bed  time,  for  duration  of  4  to  8  
weeks [3].  In gastro  esophageal  reflux  disease,  the  
recommended  dose  is 20  mg  orally, twice  a  day,  
for  a  period  of  6  to 12  weeks.  In  case  of  gastro  
esophageal  reflux,  which  is  associated with  
esophageal  ulceration;  the  recommended  dose  is  40  
mg  twice  a  day,  for  similar period [2].  The   low   
bioavailability (40 – 45%) and short biological half  
life (2.5 - 4.0 hours) [2]. 
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It   has  been  reported  that  the  oral  treatment  of  
gastric  disorders  with  an  H2  receptor antagonist,  
like  Famotidine   or  Ranitidine,   used  in  
combination  with  antacids,  promotes local  delivery  
of  these  drugs  to  the  receptors  of  parietal  cell  
wall. Local   delivery   also increases  the  stomach  
wall  receptor  site  bioavailability  and  increases  
efficacy  of  these drugs  to  reduce  acid  secretion. 
Hence  this  principle  may  be  applied  for  improving 
systemic,  as  well  as  local  delivery  of  famotidine,  
which  would  efficiently  reduce  gastric acid  
secretion[2]. 
In  the  present  investigation  floating  tablets  of  
Famotidine  were  prepared  by  effervescent approach  
using  two  different  polymers  HPMC K100 M  and  
natural  polymer  Chitosan. The aim  of  the  work  
was,  to  evaluate  the  effect  of  gel-forming  polymer  
HPMC K100M  on floating  properties  and   release  
characteristics  of  Famotidine  tablets. 
 
Materials and Method 
Materials 
Famotidine  was  received  as  a  gift  sample  from  
Tirupati  Medicare  Limited  Paonta  sahib. Chitosan, 
HPMC K100 M  and  MCC  from  Colorcon  Asia  Pvt.  
Ltd,  Sodium  bicarbonate, Citric  acid, poly  vinyl  
pyrrolidine (PVP k30), aerosil  and  Talc  were  
obtained  from  Loba chemicals.    
 
Methods 
Preparation of floating tablets of famotidine 
Effervescent  Floating  tablets  containing  Famotidine  
were  prepared  by  direct  compression technique, 
using  varying  concentrations  of  HPMC K100M, 
MCC  and  Chitosan  polymers, along  with  Sodium  
bicarbonate  and  citric  acid. All  the  ingredients  were  
accurately  weighed  and  passed  through  different  
mesh  sieves(size-40)accordingly. Then, except  for 
Magnesium  stearate,  aerosil  and  talc  all  other  
ingredients  were  blended  uniformly  in  glass mortar  
to  get  rid  of  all  the  lumps. After  sufficient   mixing   
of   drug   as   well   as  excipients, Magnesium  stearate  
was  added, as  post  lubricant  along  with  aerosil  and  
talc, as a  glidant  and  were  mixed  further  for   
additional   2-3  minutes.  The  tablets  were  directly 
compressed  using  rotary  tablet  machine (RIMEK 
Mini Press1).The  weights  of  the  tablets were  kept  
constant  for  all  formulations, that  is, 200mg [1]. 
 
 
Table 1: Formulations of famotidine floating tablets 
 
Ingredients F1 F2 F3 F4 F5 
Famotidine 20 20 20 20 20 
HPMC K100 M 45 40 40 35 45 
Chitosan 30 30 45 45 45 
MCC 35 40 25 20 10 
Citric acid  25 25 25 25 25 
Sodium bicarbonate 30 30 30 30 30 
Pvp k-30 5 5 5 5 5 
Magnesium Stearate 5 5 5 5 5 
Talc 3 3 3 3 3 
Aerosil 2 2 2 2 2 
Total  200 200 200 200 200 
              *All the quantities are in mg 
 
Evaluation of floating tablets [1,6] 
Pre-compression parameter 
Prior  to  the  compression,  the  formulations  of  
powder  blends  were  evaluated  for  their  bulk  and  
tapped  densities, respectively, and  from  these  values, 
compressibility  indices  and Hausner’s  ratio  were  
calculated. While  the  flow  properties  of  the  powder  
blend  was determined  by  calculating  the  angle  of  
repose.  
 
Angle of repose  
 
The  angle  of  repose  of  powder  blend  was  
determined  by  the  funnel  method. The  height of  the  
funnel  was  adjusted  in  such  a  way  that  the  tip  of  
the  funnel  just  touched  the  apex  of  the  powder  
blend. The  powder  blend  was  allowed  to  flow  
through  the  funnel freely  to  the  surface  until  a  
cone  was  obtained, with  its  apex  just  touching  the  
tip  of  the funnel. The  diameter  of  the  powder  cone  
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was  measured  and  angle  of  repose  was calculated  
using  the  following  equation.  
 
Tan θ = h/r 
Where, θ=tan-1 (h/r)                h = height of pile               r = radius of the base of pile 
 Different  ranges  of  flow  ability  in  terms  of  angle  of  repose  are  given  below  in  Table 2. 
Table 2: Effect of Angle of repose (θ) on Flow property 
 
 
 
 
 
 
  
 
Bulk density 
Bulk  density  was  determined  by  pouring  mass  of  
powder  into  25ml  graduated  measuring cylinder  and  
the  bulk  volume  was  noted  down. The  method  was  
repeated  three  times  and the  mean  of  the  values 
exhibited  as  final  volume  was  calculated   as  a  
result  of  bulk volume. Bulk  density  of  the  powder  
was  determined  by  applying  following  formula: 
  
Bulk density: Weight of the powder 
                       Bulk volume of powder 
 
Tapped density 
Tapped  density  was  determined  by  pouring  mass  of  
complex  and  excipients,  into  25ml graduated  
measuring  cylinder  and  graduated  cylinder  was   
then    to 10tapings, using  tapped density  apparatus, 
until  the  change  in  the  volume approached  constant  
value. The  method was  repeated  three  times  and  the  
mean  of  the  values  exhibited, was  calculated  as  a  
result of  tapped  volume. Tapped density of the  
powder was  determined by applying following 
formula:   
 
Tapped density:Weight of powder 
                            Bulk volume of powder 
 
The  simplest  way  of  measurement  of  free  flow  
property  of  powder  is  compressibility, an indication  
of  ease, with which  a  material  can  be  induced  to  
flow. Given by % compressibility index (% CI) which  
was  calculated  as  follows: 
 
Tapped density- Bulk density×100 
 Taped density 
 
Hausner’s ratio  
Hausner’s  ratio   is   an   index   of   ease   with  which   
powder   flows,  it   is  related  to  inter particulate 
friction, which  could be  used  to  predict  powder  
flow  properties. It is calculated by following  formula:  
Hausner’s ratio: Tapped density 
                         Bulk density 
 
Post- compression parameters [1,7] 
Appearance 
The   surface   of   the   tablet   was   smooth, free   
from   cracks, depressions   and   pinholes. The colour  
of  the tablet was buff white. 
  
Weight variation 
The  weight  of  the  tablets  was  routinely  determined  
to  ensure  that  the  tablets  contain proper  amount  of  
drug. The  USP  weight  variation  tests  were  done  by  
weighing  20  tablets individually, and  then  
calculating  the  average  weights  and  comparing  the  
individual weights  to  that  of  average. The  tablets  
met  the  USP  specification, according  to which  no 
more  than  2  tablets  were  outside  the  percentage  
limits  and  no  tablet  differed  by  more than  2  times   
the   percentage limit. 
 
 
Tablet hardness   
The  resistance  of  tablets  to  chipping  or  breakage  
under  condition  of  storage, transportation and  
handling  before  usage  depends  on  its  hardness. The  
hardness  of  each  batch  of  tablet was  checked  by  
using  Monsanto  hardness  tester. The  hardness  was  
measured  in  terms  of kg/cm2  six  tablets  were  
chosen  randomly  and  tested  for  hardness. The 
average hardness of six tablets was recorded.   
 
Friability   
Friability determines the resistance of tablets to 
chipping or breakage under conditions of storage, 
transportation and handling before usage. Friability 
generally refers to loss in weight of tablets in the 
Angle of repose ( θ) Type of flow 
 
<25 Excellent 
25-30 Good 
30-40 Passable 
>40 Very poor 
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containers due to removal of fines from the tablet 
surface. Friability reflects poor cohesion of tablet 
ingredients. Hence the batch was tested for chipping, 
capping, cracking or breaking. 
 
                           %F = (1 - 𝑊/𝑊 ̥̥×100) 
 
Where, W ̥ = weight of tablet before test, W = weight 
of tablet after test 
Method  
20 tablets were weighed and the initial weight of these 
tablets were recorded and placed in Roche friabilator, 
and rotated at the speed of 25 rpm for 100 revolutions. 
Then tablets were removed from the friabilator, dusted 
off the fines and again weighed and recorded.  
 
Dimensions 
The dimensions of the tablets were determined by 
thickness and diameter which were measured using 
Vernier caliper.  These values were checked and used 
to adjust the initial stages of compression. 
 
In vitro buoyancy studies  
 
The in vitro buoyancy was determined by floating lag 
time. The tablets were placed in a 100 ml beaker 
containing 0.1N hydrochloric acid (pH 1.2, 
temp.37±0.5ᵒC).The time between introduction  of  the  
dosage  form  and  its  buoyancy  in  the medium and 
the floating durations of tablets was calculated for the 
determination of lag time and total buoyancy time by 
visual  observation.  The  Time  taken  for  dosage  
form  to emerge  on  surface  of  medium  called as 
Floating Lag Time (FLT) or Buoyancy Lag Time 
(BLT) and it is the total duration of time by which 
dosage form remain buoyant. 
 
In-vitro Dissolution studies 
 
The release rate of Famotidine from floating tablets 
was determined using United States Pharmacopeia 
(USP) Dissolution Testing Apparatus 2 (paddle 
method; Veego Scientific, Mumbai, India). The 
dissolution test was performed using 900 ml of 0.1N 
hydrochloric acid, at 37 ± 0.5°C and 50 rpm. A sample 
(10 ml) of the solution was withdrawn from the 
dissolution apparatus hourly and the samples were 
replaced with fresh dissolution medium. The samples 
were filtered through a 0.45μ membrane filter and 
diluted to a suitable concentration with 0.1N 
hydrochloric acid. Absorbance of these solutions was 
measured at 265 nm using a Thermospectronic-1 
UV/Vis double-beam spectrophotometer. Cumulative 
percentage drug release was calculated using an 
equation obtained from a standard curve. 
 
 
Results and discussion[11] 
 
Evaluation of Floating Tablets 
The formulations prepared for direct compression of 
floating tablets were evaluated for their flow properties 
(table 3). The range of Angle of repose for 
formulations F5 to F1 varied between 38.65˚ to 35.09˚, 
maximum being F5 38.65˚ and minimum being F2 
38.09˚.Results of the physico-chemical characterization 
are as follows: The bulk density of the formulations F5 
to F1 ranged between 0.47gm/cm3 to 0.52gm/cm3, 
maximum being F4 0.56gm/cm3 and minimum being 
F5 0.47gm/cm3. Tapped density of formulations F5 to 
F1 ranged between 0.58gm/cm3 to 0.71gm/cm3, 
maximum being F4 0.73gm/cm3 and minimum being 
F5 0.58gm/cm3. Carr’s Index of the formulations F5 to 
F1 varied between 18.96% to 26.7%, maximum being 
F1 26.7% and minimum being F5 18.96%. Hausner’s 
ratio of the formulations F5 to F1 varied between 1.23 
to 1.36, maximum being F1 1.36 and minimum being 
F5 1.23. These values show that the prepared 
formulations have good flow properties. 
 
The weight of the tablets varied between 0.190 ± 0.006 
g to 0.210 ± 0.004 g for different formulations, with 
low standard deviation values, indicating uniformity of 
weight. The variation in weight was within the range of 
±5% complying with pharmacopoeial specifications. 
The hardness for different formulations was found to 
be between 4.02±0.03 to 5.48±0.01 kg/cm2 indicating 
satisfactory mechanical strength. The friability was 
observed to be below 2.02% for all the formulations, 
which was an indication of good mechanical resistance 
of the tablet. 
 
All the tablets were prepared by effervescent approach. 
Sodium bicarbonate was added as a gas-generating 
agent. Sodium bicarbonate induced carbon dioxide 
generation in presence of dissolution medium (0.1 N 
hydrochloric acid). The combination of sodium 
bicarbonate and citric acid provided desired floating 
ability and therefore this combination was selected for 
the formulation of the floating tablets. It was observed 
that the gas generated was trapped and protected within 
the gel, formed by hydration of polymers (HPMC 
K100M and Chitosan), thus decreasing the density of 
the tablet below one and hence making the tablet 
buoyant. The tablet was observed to swell radially and 
axially during in vitro buoyancy studies. 
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The in vitro studies showed that the Buoyancy lag time 
varied between 19 to 24 seconds, maximum of that 
being of F3 24 seconds and minimum of that being F2 
19 seconds and Floating lag time varied between 10 to 
17 hours, with F5 having more than 17hours showed 
maximum floating lag time, out of all the five 
formulations(Table 4). 
Table 3: Pre- compression parameters of direct compressed Famotidine floating tablet 
 
Formulations Angle of repose (θ) Type of flow 
F1 38.09   Passable 
F2 35.80 Passable 
F3 37.73 Passable 
F4 36.24 Passable 
F5 38.65 Passable 
 
                Batch 
 
      Bulk density 
     (g/cm3) 
Tapped density 
    (g/cm3) 
       Carr’s     
index (%) 
Hausner’s Ratio Angle of     
repose* 
F1 0.52 0.71      26.7 1.36 38.09 
F2 0.49 0.65      24.6 1.32 35.80 
F3 0.53 0.72 26.3 1.35 37.73 
F4 0.56 0.73      23.2 1.30 36.24 
F5 0.47 0.58 18.96 1.23 38.65 
 
Batch Weight 
Variation 
(g) 
Hardness 
Kg/cm2 
Thickness 
(mm) 
Diameter 
(mm) 
Friability 
(%) 
F1 0.190 ± 0.006 4.02±0.03 2.92 ± 0.112 10.08 ± 0.02 2.02 
F2 0.210 ± 0.004 5.45±0.02 2.83 ± 0.115 10.08 ± 0.01 1.13 
F3 0.200 ± 0.003 4.57±𝟎. 𝟎𝟑 3.04 ± 0.085 10.07 ± 0.01 1.65 
F4 0.206 ± 0.006 4.63±0.02 3.00 ± 0.117 10.08 ± 0.02 1.32 
F5 0.199 ± 0.004 5.48±0.01 3.54 ± 0.078 10.06 ± 0.02 1.11 
Table 4: In-Vitro buoyancy studies of Famotidine floating tablets 
Formulation  Buoyancy lag time (sec) Total floating time (Hours) 
F1 22 11 
F2 19 10 
F3 24 13 
F4 23 12 
F5 20 >17 
 
      
(Initial)                                 (After 20 sec)                                                (After 17 hrs) 
 
Figure 1: In-vitro buoyancy studies of F5 batch of Famotidine floating tablets 
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Table 6: Cumulative % drug release 
Time (in hr F1 F2 F3 F4 F5 
0.25 07.01 ±1.0 6.01±0.10 5.68±0.20 3.02±0.10 2.51±0.20 
1.00 25.68±1.20 23.38±1.20 22.93±1.40 19.01±0.70 18.90±0.30 
2.00 37.48 ±1.40 33.30±1.40 33.81±0.90 32.01±0.70 25.91±0.60 
3.00 45.01 ±1.40 37.68±1.30 39.06±10 36.90±10 32.01±0.50 
4.00 51.32±0.70 47.29±0.50 47.49±1.20 44.49±0.50 38.03±10 
5.00 61.61±2.2 52.09±0.10 58.61± 10 51.33±0.90 47.68±1.20 
6.00 72.8±0.20 60.90±0.80 60.77±1.20 56.01±0.30 50.01±0.60 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: In-vitro dissolution profile formulations 
Conclusion 
 
Hence it could be concluded that, the effervescent-
based floating drug delivery system, was a promising 
approach to achieve in vitro buoyancy of the tablet. 
The addition of gel-forming polymer HPMC K100M, 
along with natural polymer Chitosan and gas-
generating agents, sodium bicarbonate with citric acid, 
were crucial in achieving in vitro buoyancy. The drug 
release from the tablets was sufficiently sustained and 
non-Fickian transport of the drug from tablets was 
confirmed. Hence, F5 formulation showed maximum 
floating time of more than 17 hours and gave slow and 
maximum drug release. So the composition of the 
batch 5 should be optimized, to achieve the goal of 
formulation and evaluation of effervescent floating 
tablet of famotidine. 
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